Quick Answer
Xenon Pharmaceuticals Inc. reported Cash and Equivalents of $199.16 million for fiscal year 2025.
Xenon Pharmaceuticals Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $199.16M | +39.6% |
| 2024 | $142.71M | -4.0% |
| 2023 | $148.64M | +159.7% |
| 2022 | $57.24M | -67.4% |
| 2021 | $175.69M | +290.3% |
| 2020 | $45.01M | +81.8% |
| 2019 | $24.75M | -63.5% |
| 2018 | $67.75M | +230.7% |
| 2017 | $20.49M | +19.8% |
| 2016 | $17.09M | -70.9% |
| 2015 | $58.65M | -18.6% |
| 2014 | $72.03M | +89.8% |
| 2013 | $37.95M | -36.9% |
| 2012 | $60.16M | +332.0% |
| 2011 | $13.93M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $104.51M | +19.3% | -22.8% |
| June 30, 2025 | $135.38M | -1.0% | +16.1% |
| March 31, 2025 | $116.66M | +98.1% | -18.3% |
| December 31, 2024 | $142.71M | -4.0% | +62.9% |
| September 30, 2024 | $87.62M | -12.0% | -35.9% |
| June 30, 2024 | $136.73M | +111.8% | +132.2% |
| March 31, 2024 | $58.90M | -15.3% | -60.4% |
| December 31, 2023 | $148.64M | +159.7% | +49.3% |
- Xenon Pharmaceuticals Inc. showed an increase of +39.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2011–2025 period, Xenon Pharmaceuticals Inc.’s cash and equivalents has grown by 1329.9% (from $13.93 million to $199.16 million).
- The most recent figure is from Xenon Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: